Journal profile · Clinical Neurology
Alzheimers Research & Therapy
ISSN 1758-9193 · BioMed Central · United Kingdom · Founded 2009
Alzheimers Research & Therapy: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 8.91; fully open access; APC about USD 4,390; median 121 days to acceptance (126 articles, last 24 months); 292 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Alzheimers Research & Therapy is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Dementia and Cognitive Impairment Research, Alzheimer's disease research and treatments and Functional Brain Connectivity Studies, together about 65.5% of its articles. Its main subfields are Neurology. (generated from OpenAlex topic counts and CAS ranking data)
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
From the journal's Aims & Scope
Research area (LetPub): Clinical Neurology
Editor-in-chief Delphine BochePublisher website
Editorial board by country: 4 in mainland China (about 4%); most named United States 45, United Kingdom 12, Italy 8, Canada 5, Netherlands 5 (112 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Dementia and Cognitive Impairment ResearchMedicine31.2%
- Alzheimer's disease research and treatmentsMedicine29.5%
- Functional Brain Connectivity StudiesNeuroscience4.8%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience2.9%
- Intracerebral and Subarachnoid Hemorrhage ResearchMedicine2.9%
- Neurological Disease Mechanisms and TreatmentsNeuroscience2.8%
- Cholinesterase and Neurodegenerative DiseasesMedicine2.7%
- Amyotrophic Lateral Sclerosis ResearchMedicine2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Clinical Neurology | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Clinical Neurology | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Clinical Neurology | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 8.91LetPub ·
- Impact factor (publisher) 2025
- 8.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 9.8Publisher website ·
- CiteScore 2026-06
- 12.8LetPub ·
- SJR 2026-06
- 2.48LetPub ·
- SNIP 2026-06
- 1.81LetPub ·
- h-index
- 53LetPub ·
- h-index
- 149OpenAlex ·
- i10-index
- 1,646OpenAlex ·
- 2-year mean citedness
- 9.58OpenAlex ·
- Self-citation rate
- 3.4%LetPub ·
- Share of gold OA articles
- 99.87%LetPub ·
Volume
- Articles per year
- 281LetPub ·
- Downloads per year (publisher) 2025
- 3,300,000Publisher website ·
Articles by year OpenAlex count · 2,396 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 261 | 261 | 161 |
| 2025 | 292 | 292 | 2,525 |
| 2024 | 279 | 279 | 5,288 |
| 2023 | 221 | 221 | 5,725 |
| 2022 | 202 | 202 | 8,289 |
| 2021 | 203 | 203 | 11,656 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
121 daysMedian, submission to acceptance · P25–P75 91 days – 176 days
- Acceptance to online
- median 14 days (126 articles)
- Submission to online
- median 146 days
- Sample
- 126 articles with submission and acceptance dates (606 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Unspecified peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,490 / USD 4,390 / GBP 3,090 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 4,290 / EUR 3,390 / GBP 2,990 | — | — | |
| LetPub | GBP 2,790 / USD 3,990 / EUR 3,190 | Yes | — | |
| Publisher website | GBP 3,090 / USD 439 / USD 4,390 / EUR 3,490 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
- New voices in biomarker research for neurodegenerative diseasesDeadline
- Neuromodulation in Neurodegenerative Disorders: Novel TMS Approaches and Protocols Targeting Cognition, Mood, and BiomarkersDeadline
- Real-World Implementation of Blood-Based Biomarkers for Neurodegenerative and Neuroinflammatory DiseasesDeadline
What to prepare1 items from the author guidelines
- Suggested reviewers
- Optional
Article types accepted8
- commentResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- correspondenceResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- debatesResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- matters arisingResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- meeting reportsResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- mini reviewResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- research articlesResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
- reviewsResearch articles Debates Comment Correspondence Meeting reports Reviews Mini review Matters ArisingLength not stated
Policy excerpts from the journal's websiteData availability, License & copyright, Open access, Peer review
- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing strongly encouraged or required; deposit in public repositories where appropriate. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Published under CC BY-NC-ND or CC BY licence. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Alzheimer's Research & Therapy articles are published open access under a CC BY-NC-ND (Creative Commons Attr…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- United Kingdom
- Language
- English
- Founded
- 2009
- ISSN
- 1758-9193
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Alzheimers Research & Therapy
What CAS zone is Alzheimers Research & Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Alzheimers Research & Therapy is in Zone 1 of Medicine, and in Zone 1 of the minor category Clinical Neurology / Neurosciences; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Alzheimers Research & Therapy?
The latest impact factor listed by LetPub is 8.91; CiteScore 12.8, h-index 149.
How long does peer review take at Alzheimers Research & Therapy?
Based on the dates recorded on 126 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 121 days (interquartile range 91–176 days); authors report an average review time of over 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Alzheimers Research & Therapy based?
Of the 112 board members whose country the journal's board page names, 4 (about 4%) are in mainland China; the countries named most often are United States (45), United Kingdom (12) and Italy (8). Counted from the institutions listed on the board page; for reference only.
Which databases index Alzheimers Research & Therapy?
According to LetPub and DOAJ records, Alzheimers Research & Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Alzheimers Research & Therapy open access, and what is the APC?
Alzheimers Research & Therapy is a fully open-access journal. APC about USD 4,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .